TGFB1 and neoplasm: In this phase I clinical trial, YL-13027 monotherapy showed a good safety profile and retarded tumor growth, demonstrating that targeting p-EMT and thus inhibiting the TGF-β pathway is a novel strategy for SBC treatment.